OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck's KEYTRUDA® (pembrolizumab)
Stock Information for OncoSec Medical Incorporated
Loading
Please wait while we load your information from QuoteMedia.